108 related articles for article (PubMed ID: 32915889)
1. --A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS.
Nicholas TR; Meng J; Greulich BM; Morris TS; Hollenhorst PC
PLoS One; 2020; 15(9):e0238999. PubMed ID: 32915889
[TBL] [Abstract][Full Text] [Related]
2. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
[TBL] [Abstract][Full Text] [Related]
4. An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.
Kedage V; Selvaraj N; Nicholas TR; Budka JA; Plotnik JP; Jerde TJ; Hollenhorst PC
Cell Rep; 2016 Oct; 17(5):1289-1301. PubMed ID: 27783944
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S
Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692
[TBL] [Abstract][Full Text] [Related]
6. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Wang X; Qiao Y; Asangani IA; Ateeq B; Poliakov A; Cieślik M; Pitchiaya S; Chakravarthi BVSK; Cao X; Jing X; Wang CX; Apel IJ; Wang R; Tien JC; Juckette KM; Yan W; Jiang H; Wang S; Varambally S; Chinnaiyan AM
Cancer Cell; 2017 Apr; 31(4):532-548.e7. PubMed ID: 28344039
[TBL] [Abstract][Full Text] [Related]
7. Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors.
Currie SL; Warner SL; Vankayalapati H; Liu X; Sharma S; Bearss DJ; Graves BJ
SLAS Discov; 2019 Jan; 24(1):77-85. PubMed ID: 30204534
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
[TBL] [Abstract][Full Text] [Related]
9. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
Blee AM; Liu S; Wang L; Huang H
Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
11. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
Winters B; Brown L; Coleman I; Nguyen H; Minas TZ; Kollath L; Vasioukhin V; Nelson P; Corey E; Üren A; Morrissey C
Anticancer Res; 2017 Jul; 37(7):3385-3396. PubMed ID: 28668826
[TBL] [Abstract][Full Text] [Related]
13. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer.
Shinde D; Albino D; Zoma M; Mutti A; Mapelli SN; Civenni G; Kokanovic A; Merulla J; Perez-Escuredo J; Costales P; Morìs F; Catapano CV; Carbone GM
Eur Urol Oncol; 2019 Jul; 2(4):415-424. PubMed ID: 31277777
[TBL] [Abstract][Full Text] [Related]
15. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
[TBL] [Abstract][Full Text] [Related]
16. The ERG-Regulated
Angeles AK; Heckmann D; Flosdorf N; Duensing S; Sültmann H
Mol Cancer Res; 2020 Oct; 18(10):1545-1559. PubMed ID: 32646965
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells.
Kallal LA; Waszkiewicz A; Jaworski JP; Della Pietra A; Berrodin T; Brady P; Jurewicz AJ; Zeng X; Payne L; Medina JR; Doepner-Buser C; Mangatt B
SLAS Discov; 2021 Feb; 26(2):216-229. PubMed ID: 33482073
[TBL] [Abstract][Full Text] [Related]
20. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
Mounir Z; Korn JM; Westerling T; Lin F; Kirby CA; Schirle M; McAllister G; Hoffman G; Ramadan N; Hartung A; Feng Y; Kipp DR; Quinn C; Fodor M; Baird J; Schoumacher M; Meyer R; Deeds J; Buchwalter G; Stams T; Keen N; Sellers WR; Brown M; Pagliarini RA
Elife; 2016 May; 5():. PubMed ID: 27183006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]